What Голдлайн Treats: Main Uses and Benefits

Голдлайн was commonly used to help with the pharmacological management of exogenous obesity in adults. This treatment was generally intended for individuals with a Body Mass Index (BMI) of 30 kg/m^2 or greater, or those with a BMI of 27 kg/m^2 or greater who also presented with coexisting metabolic conditions like Type 2 Diabetes or dyslipidemia.

The medication was applied in clinical settings where patients required supportive management for symptoms related to heightened physiological activity that manifests as a persistent increased appetite and difficulty in achieving satiety (fullness). This supportive role contributes to the goal of clinically significant body weight reduction as an adjunct to medically supervised diet and exercise programs. The treatment was relevant for addressing symptom clusters related to excessive body weight.

Quick Fact: Managing Appetite

The treatment was relevant for addressing symptom clusters related to excessive body weight, which included a persistent increased appetite and difficulties in maintaining a sense of fullness required for long-term caloric restriction.

Who Can and Cannot Use Голдлайн (Sibutramine)?

Regulatory documents define strict eligibility criteria for sibutramine, predominantly excluding populations due to established cardiovascular risks. Use is primarily restricted to adults who meet specific weight criteria and are free of all contraindications.

---

Eligibility and Exclusion Criteria

Classification	Rule (Official Regulatory Status)
Eligible Population	Adults aged 18 to 65 years with an initial BMI ge 30 kg/m^2, or BMI ge 27 kg/m^2 with coexisting risk factors like Type 2 Diabetes or dyslipidemia.
Age Restriction	Contraindicated in patients under 18 and over 65 years of age.
Absolute Contraindication	Patients with a history of coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, or major eating disorders (anorexia/bulimia).
Organ Function/Conditions	Contraindicated in severe hepatic or renal impairment, hyperthyroidism, and narrow-angle glaucoma.
Reproductive Status	Use is contraindicated during pregnancy and not recommended during breastfeeding/lactation.

---

Eligibility Summary

Sibutramine eligibility is structurally defined by exclusion. A patient is only permitted to use the medicine if they meet the specific BMI inclusion criteria and are certified as free of the listed absolute contraindications, particularly those involving cardiovascular and cerebrovascular history, as stated in the official regulatory prescribing information.

Interactions with other medicines and products

The official regulatory profile for Голдлайн (Sibutramine) is defined by several documented interaction classifications and restrictions.

---

Contraindicated Combinations

• Monoamine Oxidase Inhibitors (MAOIs): Co-administration is contraindicated, and official labeling requires a 14-day separation period before starting or stopping sibutramine.
• Other Centrally-Acting Anorectics: Use with other medicines intended for weight loss is prohibited.

---

Clinically Significant Pharmacokinetic Interactions

Sibutramine is primarily metabolized by the CYP3A4 enzyme. Regulatory documents note that co-administration with strong CYP3A4 inhibitors (such as Ketoconazole and Erythromycin) results in increased plasma concentrations (AUC) of the active metabolites. Conversely, CYP3A4 inducers (e.g., Carbamazepine) may decrease exposure.

Clinically Significant Pharmacodynamic Interactions

• Serotonergic Agents: Concurrent use with other drugs that raise serotonin levels (e.g., SSRIs, Triptans, Lithium, Tryptophan) is associated with the risk of Serotonin Syndrome due to additive effects.
• Sympathomimetics: Combining with substances that may raise blood pressure or heart rate (e.g., Ephedrine, Pseudoephedrine in cold remedies) may lead to additive sympathomimetic effects.
• Antiplatelet Agents: Use with medicines affecting haemostasis (e.g., Aspirin, Warfarin) is cautioned due to a potential increase in bleeding risk.

---

Population-Specific Restrictions

The product is contraindicated in patients with severe hepatic impairment and severe renal impairment due to altered metabolite exposure and clearance.

Neurotransmitter Reuptake Inhibition

The active substance and its primary metabolites function as reuptake inhibitors targeting the serotonin (5-HT) and norepinephrine (NE) transporters (SERT and NET) in the central nervous system. This action blocks the transporters from reabsorbing these neurotransmitters back into the presynaptic neuron, thereby increasing and prolonging the concentration of 5-HT and NE in the synaptic clefts of the brain. The sustained elevation of synaptic 5-HT and NE levels within key brain regions, such as the hypothalamus, results in modulated signaling within appetite regulatory circuits, leading to altered physiological responses.

Central Appetite Regulation and Modulation

The heightened availability of serotonin acts predominantly within the hypothalamic nuclei, which are involved in hunger and satiety signaling, to enhance and prolong the signals that communicate a state of fullness. This modulation of satiety signaling modifies the activity of the feeding control pathway, contributing to the resulting physiological change of reduced spontaneous food intake and decreased energy consumption.

Modulation of Energy Expenditure

The increased concentration of norepinephrine acts on receptors in the central nervous system, which in turn stimulates the sympathetic nervous system (SNS). This promotes a mild increase in the body's energy output by slightly enhancing thermogenesis (heat production) and the overall basal metabolic rate. This mechanistic cascade contributes to a shift in energy balance by slightly increasing energy expenditure, which defines the observable physiological effect.

The medication Голдлайн, which contains the active substance sibutramine, was administered exclusively by the oral route as a hard capsule, intended to be swallowed whole with liquid. The official instructions established its role as an adjunctive therapy within a comprehensive, physician-supervised weight management program. The medicine may be taken with or without food and is generally administered once daily in the morning to maintain a consistent schedule.

Official Dosing Regimen

The standard adult therapy begins with a starting dose of 10 mg once daily. Following the initial four weeks of use, the dose could be adjusted to the maximum recommended dose of 15 mg per day if the procedural weight loss response was below a predefined minimum threshold. Doses exceeding 15 mg daily are not officially recommended by regulatory authorities. For patients unable to tolerate the standard 10 mg starting dose, a lower 5 mg dose was established as an alternative option.

Treatment Course and Specific Use Constraints

The maximum treatment duration was generally 12 months (one year). Continuation of the regimen beyond the first three months was explicitly linked to meeting specific weight loss criteria outlined in the regulatory documents, ensuring a structured treatment plan. The official instructions for a missed dose specify that the patient should skip the missed dose entirely and resume the regular once-daily schedule the following day, rather than attempting to take a doubled dose. Furthermore, use was not established for patients under 16 years of age and was not recommended in cases of severe renal or severe hepatic impairment.

The clinical evidence for sibutramine, the active pharmaceutical ingredient in Голдлайн, primarily consists of Randomized Controlled Trials (RCTs) that tracked and measured the change in body weight and BMI in adults with exogenous obesity (BMI ge 30 kg/m^2). These studies were typically short-term, lasting six months to one year. Findings describe patterns observed in the studies where the change in body weight was generally a small-to-moderate difference when compared to the changes measured in the placebo groups. Research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Sibutramine was evaluated in specific subgroups of patients classified as overweight or obese who also presented with metabolic risk factors, such as Type 2 Diabetes or dyslipidemia. Studies monitored specific measurements, including metabolic markers like blood lipid levels and glycosylated hemoglobin (HbA1c). Studies report measured changes in these biomarkers, but data for certain groups remain insufficient and follow-up durations were limited, often spanning only up to one year.

Research explored the issue of weight maintenance through specific long-term protocols, sometimes lasting up to two years. Studies monitored patient responses over defined time intervals, with data showing patterns related to the measured change in the amount of weight regain that occurred. However, what is not fully established is the sustained change over time for periods longer than two years. The overall research landscape notes that certainty remains low for long-term effects, and the results apply only to the populations studied in the RCTs. Research describes limited data for special populations like adolescents, and comparative evidence is lacking for other treatments.

Key Studies & References

1. Sibutramine (STORM) Trial: A randomized controlled trial of sibutramine for weight loss maintenance

Common questions about Голдлайн (FAQ)

---

Q: What is the difference between Голдлайн and other treatments for weight management?

Official research documents describe the patterns of weight change observed in the studied populations. However, the same documents note that comparative evidence that directly assesses this drug against other weight-loss treatments is generally lacking. The research is focused on the drug's effect compared to placebo, not to other active treatments.

---

Q: Is Голдлайн considered a stimulant?

The active substance is officially categorized as a Serotonin–norepinephrine reuptake inhibitor (SNRI), which acts in the central nervous system. Because its mechanism involves stimulating the sympathetic nervous system, regulatory sources also describe it as a centrally-acting stimulant and a Schedule IV controlled substance.

---

Q: Is Голдлайн appropriate for people who only need to lose a small amount of weight?

Official eligibility criteria define specific body weight criteria for use. The drug is typically restricted to adults with an initial Body Mass Index (BMI) of 30 kg/m^2 or greater, or a BMI of 27 kg/m^2 or greater with coexisting risk factors, such as Type 2 Diabetes.

---

Q: Are there known interactions between Голдлайн and common over-the-counter pain relievers?

Official product labeling includes a caution regarding concurrent use with certain medications that affect blood clotting. Specifically, using this drug with antiplatelet agents (which include some common pain relievers like aspirin) is associated with a potential increase in bleeding risk.

---

Q: Can alcohol be consumed while taking Голдлайн?

Official product information indicates that combining this drug with alcohol may heighten the risk of certain side effects. These can include effects on the cardiovascular system, such as an increased heart rate, and on the nervous system, such as dizziness.

---

Q: Does Голдлайн require regular monitoring by a healthcare professional?

According to official documents, use of this drug is described as being part of a physician-supervised program. Regulatory warnings state that regular monitoring of blood pressure and heart rate is critical throughout the course of treatment.

---

Q: Why might a doctor prescribe a lower dose of Голдлайн to start?

Official dosing guidelines established a lower starting dose as an alternative option. This mathbf5 mg dose was designated for adult patients who were unable to tolerate the standard mathbf10 mg starting dose.

---

Q: If I miss a dose of Голдлайн, what is the usual recommendation?

The official instructions for managing a missed dose specify that the patient should skip the missed dose entirely. The regulatory documents state that the official instructions are to resume the regular once-daily dosing schedule the following day, rather than attempting to take a doubled dose.

---

Q: Can people with diabetes use Голдлайн?

Adults who meet specific weight criteria (BMI of 27 kg/m^2 or greater) and have coexisting metabolic risk factors are included in the defined eligible population. Type 2 Diabetes is specifically listed in regulatory documents as one such factor.

---

Q: Is the goal of Голдлайн treatment to achieve a specific weight percentage loss?

Continuation of the treatment regimen beyond the initial three months was explicitly linked to meeting specific clinical requirements. These requirements involve achieving a predefined minimum weight loss percentage, which is outlined in the official regulatory documents.

---

Q: Is Голдлайн used for anything other than weight management?

Official product information defines the historical purpose of this drug as being for the long-term management of exogenous obesity (weight gain due to calorie intake), in conjunction with diet and exercise. Use for other purposes is not included in the official indication.

---

Q: Does Голдлайн cause addiction or dependence?

The active substance is classified by the Drug Enforcement Administration (DEA) as a Schedule IV controlled substance. This classification category is defined as having a low potential for abuse relative to certain other controlled substances.

---

Q: Is there an age limit for starting treatment with Голдлайн?

Official regulatory documents define a strict age range for use. The drug is intended for adults aged 18 to 65 years and is contraindicated (should not be used) in patients both under 18 and over 65 years of age.

---

Q: Does taking Голдлайн affect driving or operating machinery?

Official warnings state that this drug may impair the ability to think or react in some patients. Regulatory advice advises patients to be cautious regarding activities like driving or operating heavy machinery until the medication’s effect on them is known.

---

Q: Can Голдлайн be used by people with thyroid issues?

The drug is contraindicated (should not be used) in patients with hyperthyroidism (an overactive thyroid gland). Official warnings note that patients with an underactive thyroid should discuss this with a healthcare professional before starting treatment.

---

Q: Is Голдлайн used as a short-term or long-term treatment?

The drug was historically intended for the long-term management of obesity, combined with lifestyle adjustments. Official regulatory documents generally defined a maximum treatment duration of 12 months (one year).

---

Q: What is the difference between the capsule form and other potential forms of Голдлайн?

According to official prescribing information, the medication was administered exclusively by the oral route as a hard capsule, intended to be swallowed whole with liquid. Other forms are not defined in the regulatory documents.

---

Q: What evidence is there regarding the drug's effect on cholesterol levels?

Studies conducted on the drug monitored specific measurements, including metabolic markers like blood lipid levels and glycosylated hemoglobin (HbA1c). Research reports measured changes in these biomarkers in the studied patient populations.

---

Q: How does the official definition of drug dependence apply to Голдлайн?

The active substance is classified as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA). This regulatory classification is defined as having a low potential for abuse relative to controlled substances in the Schedule III category.

How to Store and Dispose of Голдлайн? (Sibutramine)

The official storage and disposal requirements for Голдлайн are mandated by regulatory agencies, reflecting the need to maintain product stability and adhere to controlled substance protocols.

---

Official Storage Requirements

Storage Detail	Requirement Based on Official Labeling
Temperature	Store at Controlled Room Temperature (CRT), typically 20 C to 25 C (68 F to 77 F).
Protection	Keep in a tightly closed container and ensure protection from moisture.
Safety	Must be stored out of the sight and reach of children.

---

Handling and Disposal

As a Schedule IV controlled substance, Голдлайн disposal is subject to specific government regulations. Unused or expired medication must not be flushed down a toilet or poured down a drain. Disposal should follow the official guidance for controlled substances, typically involving participation in an authorized drug take-back program or following secure disposal protocols at home.